ArticleGastro hep advances2024
Lower Incidence of HCC and Other Major Adverse Liver Outcomes in People Living With HIV and Chronic Liver Disease.
Article in Gastro hep advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: People living with human immunodeficiency virus (HIV) (PLWH) show a high incidence of chronic liver disease (CLD). However, whether HIV is associated with major adverse liver outcomes (MALO) in patients with underlying CLD remains to be determined. Methods: In this population-based cohort study, data were retrieved from the Swedish National Patient Register to identify PLWH and CLD (n = 2375) or CLD without HIV (n = 144,346) between 1997 and 2020. The cumulative incidence of MALO was calculated while accounting for competing risks (non-MALO death). Incidence rates per 1000 person-years were compared between the exposure groups (HIV vs no HIV) with Cox regression to estimate adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs). Results: The incidence rate per 1000 person-years of MALO was lower in PLWH (5.1, 95% CI 4.2-6.1) compared to patients without HIV (13.1, 95% CI 12.9-13.3). This translated into an adjusted HR of 0.77 (95% CI 0.64-0.93), driven by a lower rate of hepatocellular carcinoma (adjusted HR = 0.61, 95% CI 0.43-0.86). Consistent results were noted across a range of subgroup analyses. The 10-year cumulative incidence of MALO was lower in PLWH (5.0%, 95% CI 4.1-6.1) than in patients without HIV (10.9%, 95% CI 10.7-11.0). Conclusion: Among patients with CLD, the risk of MALO was lower in PLWH compared to those without HIV, primarily due to a lower incidence of hepatocellular carcinoma. These results suggest that HIV is not associated with a higher risk of MALO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.